June 10, 2026 -- XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, today announced a strategic partnership with a prominent international biopharmaceutical company. The collaboration focuses on developing a best-in-class small molecule against a G protein-coupled receptor (GPCR). This agreement builds upon a rigorous and successful pilot phase, where XtalPi's integrated quantum physics and AI algorithms delivered breakthrough hit rates, conf

June 10, 2026 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced that the National Medical Products Administration (NMPA) of China has accepted the Investigational New Drug (IND) application for HBM7004 for the treatment of advanced solid tumors. HBM7004 is a novel B7H4xCD3 bispecific antibody developed using the Company's HBI

June 9, 2026 -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, today announced a significant clinical milestone achieved by its global partner, Formation Bio. Formation Bio announced the dosing of the first participant in a Phase 1, first-in-human clinical trial (BLKR201-101-HV) evaluating BLKR201 (originally designated as LNK01006). The study is a single ascending dose (SAD) and mult

Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at PSNI collaborates with Seattle-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier, and deliver proprietary immunotherapeutic directly into patients' tumors, rather than intravenously June 9, 2026 -- A collaboration involving Providence Swedish Neuroscience Institute (PSNI) recently concluded initial testing of a novel immunotherapy research project for the treatment of glioblastoma (GBM). Th

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young children Rare pediatric disease designation provides for a Priority Review Voucher (PRV) subject to certain conditions This new designation is in addition to opaganib's current neuroblastoma orphan drug designation, providing for potential benefits such as accelerated development and review times, F

Rejuvenate Bio, a biotechnology company developing gene therapies for age-related and chronic diseases, today announced the closing of a $6 million financing round led by VCapital, with participation from Merck Animal Health, Kendall Capital Partners, Connecticut Innovations and Digitalis. In addition to the financing, Rejuvenate Bio and Merck Animal Health have entered into a strategic research and development collaboration focused on advancing a novel gene therapy program in animal health. T

June 8, 2026 -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in Parkinson's disease in the SLEIPNIR Phase 2a platform trial, in collaboration with Haukeland University Hospital, Bergen, Norway. SLEIPNIR is a multi-arm Phase 2a clinical trial platform designed to evaluate investigational disease-modifying therapies in Parkinson's disease, with focus on brain penetration, biological ta

Incyte announced Monday an agreement to acquire Vega Therapeutics, a wholly-owned subsidiary of Star Therapeutics, for up to $2 billion, confirming rumours first reported by the Financial Times a day earlier. The deal — which includes $1.25 billion upfront — is focused on the investigational monoclonal antibody VGA039 for von Willebrand disease (VWD). "VGA039 fits directly into our strategy of building a top-tier growth company for the future," said Incyte CEO Bill Meury, who took up the reins

Roche is wagering billions of dollars on a medicine that trashes a troublesome protein instead of stifling its activity. The Swiss drugmaker on Monday reached a deal with Nurix Therapeutics to codevelop a therapy called bexobrutideg that’s nearing late-stage testing. Roche will pay Nurix $700 million up front and, in return, will split U.S. rights to the drug while gaining full ownership elsewhere. Roche will also cover 60% of the development costs and hand Nurix royalties on non-U.S. sales. N

June 8, 2026 - Kye Pharmaceuticals Inc. ("Kye"), a Canadian-based specialty pharmaceutical company focused on licensing and commercializing innovative medicines for patients in Canada, today announced that Dyanavel® XR (amphetamine extended-release) tablets are now available through pharmacies and wholesalers nationwide. Dyanavel® XR is authorized for sale in Canada for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults aged 18 years and older, as well as in children age